De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression

Antimetabolites were the first chemotherapies, yet many have failed in the clinic due to toxicity and poor patient selection. Our data suggest that p16 loss provides a therapeutic window to kill cancer cells with widely-used antifolates with relatively little toxicity.